Addressing Treatment Options for Multiple Myeloma

0 reviews

Haymarket Medical Education

30 minutes

PROGRAM DESCRIPTION
Multiple myeloma (MM) is a malignant B-cell lymphoproliferative disorder that is the second most common hematologic malignancy, accounting for approximately 10% of hematologic cancers. Despite significant advances in MM care over the last several decades, nearly all patients relapse after first-line therapy. Identification of relapsed patients who require additional treatment and selection of an appropriate management strategy are critical decisions in long-term care of patients with MM. Choosing the wrong regimen can potentially preclude or compromise future treatment options, resulting in less-than-optimal long-term outcomes. Observation and close monitoring is an appropriate strategy for some patients with biochemical evidence of relapse, while patients with certain high-risk cytogenetic features or clinical evidence of disease progression require pharmacologic therapy. Clinicians must be able to develop individualized treatment plans that consider factors such as patient characteristics (eg, age, performance status), prior lines of therapy and response to therapy, prior adverse events, quality of life, and the patient’s treatment goals. Recent research has identified several new approaches that can improve outcomes for patients with relapsed MM, including new antitumor agents, multidrug combinations, and extended treatment regimens.

EDUCATIONAL OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:IDENTIFY relapsing patients with MM who require immediate treatment, as well as those who are candidates for close observation and monitoring.EVALUATE the most current data and clinical applications for approved and emerging treatment options in MM.FORMULATE individualized treatment plans for MM using patient case scenarios.The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.